To further investigate the GGR deficiency in melanoma and its possible clinical implications we investigated XPC, DDB1 and DDB2 expression in a cohort of 196 primary and metastatic melanomas (clinical details in Supplementary Table 1). This evidence concerns the gene DDB2 and metastatic melanoma.